{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:06:04Z","timestamp":1789553164996,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":1033,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1136\/esmoopen-2018-000348","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T09:16:08Z","timestamp":1528881368000},"page":"e000348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Empirical antimicrobial treatment in haemato-\/oncological patients with neutropenic sepsis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-7173","authenticated-orcid":false,"given":"Matthias Gerhard","family":"Vossen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Milacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Thalhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2018-000348_bb0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00134-015-3965-0","article-title":"Understanding the risk for infection in patients with neutropenia","volume":"42","author":"Klastersky","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2217\/fmb-2015-0014","article-title":"Multidrug-resistant bacteria in hematology patients: emerging threats","volume":"11","author":"Tatarelli","year":"2016","journal-title":"Future Microbiol"},{"key":"10.1136\/esmoopen-2018-000348_bb0020","first-page":"141","article-title":"Blood culture in neutropenic patients with fever","volume":"3","author":"Meidani","year":"2012","journal-title":"Int J Prev Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0025","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0030","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2018-000348_bb0040","first-page":"1487","article-title":"The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients","volume":"21","author":"Klastersky","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2018-000348_bb0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10147-015-0853-0","article-title":"A new prognostic model for chemotherapy-induced febrile neutropenia","volume":"21","author":"Ahn","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1136\/esmoopen-2018-000348_bb0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1136\/esmoopen-2018-000348_bb0055","author":"Apfalter","year":"2016","journal-title":"Resistenzbericht \u00d6sterreich 2015, Bundesministerium f\u00fcr Gesundheit und Frauen (BMGF)"},{"key":"10.1136\/esmoopen-2018-000348_bb0060","unstructured":"Centers for Disease Control and Prevention. Active Bacterial core surveillance report, emerging infections program network, methicillinresistant staphylococcus aureus, 2015."},{"key":"10.1136\/esmoopen-2018-000348_bb0065","author":"Public Health Agency of Canada","year":"2016","journal-title":"Canadian antimicrobial resistance surveillance system-report"},{"key":"10.1136\/esmoopen-2018-000348_bb0070","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(06)68853-3","article-title":"Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat","volume":"368","author":"Grundmann","year":"2006","journal-title":"Lancet"},{"issue":"suppl_1","key":"10.1136\/esmoopen-2018-000348_bb0075","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace","volume":"215","author":"Logan","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0080","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"key":"10.1136\/esmoopen-2018-000348_bb0085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1017\/ice.2017.42","article-title":"Carbapenem-resistant Enterobacteriaceae: a strategic roadmap for infection control","volume":"38","author":"Friedman","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1136\/esmoopen-2018-000348_bb0090","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"10.1136\/esmoopen-2018-000348_bb0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/QCO.0b013e3283630dd3","article-title":"The intestinal microbiota and susceptibility to infection in immunocompromised patients","volume":"26","author":"Taur","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijantimicag.2016.11.009","article-title":"Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008\u20132013","volume":"49","author":"Chen","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1136\/esmoopen-2018-000348_bb0105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/21505594.2016.1156821","article-title":"Bloodstream infections in neutropenic cancer patients: a practical update","volume":"7","author":"Gustinetti","year":"2016","journal-title":"Virulence"},{"key":"10.1136\/esmoopen-2018-000348_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.diagmicrobio.2017.05.003","article-title":"Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome","volume":"88","author":"Tofas","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0115","series-title":"Neutropenic sepsis guidelines","first-page":"1","author":"Bell","year":"2010"},{"key":"10.1136\/esmoopen-2018-000348_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","article-title":"Survival in neutropenic patients with severe sepsis or septic shock","volume":"40","author":"Legrand","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0125","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.7326\/0003-4819-119-12-199312150-00003","article-title":"Infectious morbidity associated with long-term use of venous access devices in patients with cancer","volume":"119","author":"Groeger","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2013.12.006","article-title":"Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients","volume":"68","author":"Mikulska","year":"2014","journal-title":"J Infect"},{"key":"10.1136\/esmoopen-2018-000348_bb0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1469-0691.1997.tb00614.x","article-title":"Empirical antibacterial treatment for sepsis and the role of glycopeptides: recommendations from a European panel","volume":"3","author":"Pittet","year":"1997","journal-title":"Clin Microbiol Infect"},{"key":"10.1136\/esmoopen-2018-000348_bb0140","series-title":"Annual report of the resistance surveille network (EARS-Net)","first-page":"65","article-title":"Antimicrobial resistance surveillance in Europe2015","author":"European Centre for Disease Prevention and Control","year":"2017"},{"key":"10.1136\/esmoopen-2018-000348_bb0145","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s15010-013-0524-x","article-title":"Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals","volume":"42","author":"Schwab","year":"2014","journal-title":"Infection"},{"key":"10.1136\/esmoopen-2018-000348_bb0155","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s15010-002-2094-1","article-title":"Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer","volume":"30","author":"Lehrnbecher","year":"2002","journal-title":"Infection"},{"key":"10.1136\/esmoopen-2018-000348_bb0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2431-5-10","article-title":"Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia","volume":"5","author":"Hodgson-Viden","year":"2005","journal-title":"BMC Pediatr"},{"key":"10.1136\/esmoopen-2018-000348_bb0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2016.09.002","article-title":"The rapid spread of carbapenem-resistant Enterobacteriaceae","volume":"29","author":"Potter","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1136\/esmoopen-2018-000348_bb0175","author":"Thenmozhi","year":"2014","journal-title":"Antibiotic resistance mechanism of ESBL producing Enterobacteriaceae in clinical field: a review"},{"key":"10.1136\/esmoopen-2018-000348_bb0180","series-title":"Activity of aztreonam combined with the beta-lactamase inhibitor avibactam tested against metallo-\u03b2-lactamase-producing organisms","author":"Castanheira","year":"2013"},{"key":"10.1136\/esmoopen-2018-000348_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01224-17","article-title":"New Delhi metallo-\u03b2-lactamase-1 catalyses avibactam and aztreonam hydrolysis","author":"Lohans","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1136\/esmoopen-2018-000348_bb0190","first-page":"1","article-title":"Antimicrobial susceptibility profile of extended spectrum \u03b2-lactamase (ESBL) producing Escherichia coli from various clinical samples","volume":"7","author":"Kumar","year":"2014","journal-title":"Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0195","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0200","doi-asserted-by":"crossref","first-page":"20140080","DOI":"10.1098\/rstb.2014.0080","article-title":"Surveillance of antibiotic resistance","volume":"370","author":"Johnson","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1136\/esmoopen-2018-000348_bb0205","doi-asserted-by":"crossref","first-page":"ofx101","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of ceftazidime\u2013avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0210","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00537-17","article-title":"Resistance to ceftazidime\u2013avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1136\/esmoopen-2018-000348_bb0215","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime\u2013avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae?","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1136\/esmoopen-2018-000348_bb0225","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime\u2013avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1136\/esmoopen-2018-000348_bb0230","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1128\/AAC.01989-12","article-title":"Human simulated studies of aztreonam and aztreonam\u2013avibactam to evaluate activity against challenging gram-negative organisms, including metallo-\u03b2-lactamase producers","volume":"57","author":"Crandon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1136\/esmoopen-2018-000348_bb0235","doi-asserted-by":"crossref","first-page":"w14281","DOI":"10.4414\/smw.2016.14281","article-title":"Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia","volume":"146","author":"Schmiedel","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"10.1136\/esmoopen-2018-000348_bb0240","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3324\/haematol.2012.061952","article-title":"The role of antifungal treatment in hematology","volume":"97","author":"Maertens","year":"2012","journal-title":"Haematologica"},{"key":"10.1136\/esmoopen-2018-000348_bb0245","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"Skiada","year":"2013","journal-title":"Haematologica"},{"key":"10.1136\/esmoopen-2018-000348_bb0250","first-page":"193","article-title":"Voriconazol: therapiemanagement und plasmaspiegeloptimierung in der therapie invasiver aspergillosen","volume":"34","author":"Karthaus","year":"2016","journal-title":"AMT"},{"key":"10.1136\/esmoopen-2018-000348_bb0255","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2007.10.002","article-title":"Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation","volume":"27","author":"Groetzner","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"Suppl 1","key":"10.1136\/esmoopen-2018-000348_bb0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1439-0507.2008.01528.x","article-title":"Caspofungin for treatment of invasive aspergillus infections","volume":"51","author":"Heinz","year":"2008","journal-title":"Mycoses"},{"key":"10.1136\/esmoopen-2018-000348_bb0270","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1136\/esmoopen-2018-000348_bb0275","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1086\/527382","article-title":"1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia","volume":"46","author":"Senn","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0280","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2017.10661","article-title":"Aspergillus galactomannan for diagnosing invasive aspergillosis","volume":"318","author":"Miceli","year":"2017","journal-title":"JAMA"},{"key":"10.1136\/esmoopen-2018-000348_bb0285","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/cid\/cis456","article-title":"(1,3)-\u03b2-D-glucan as a prognostic marker of treatment response in invasive candidiasis","volume":"55","author":"Jaijakul","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1136\/esmoopen-2018-000348_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2017.07.006","article-title":"2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan","author":"Kung","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1136\/esmoopen-2018-000348_bb0295","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/annonc\/mdq442","article-title":"Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology","volume":"22","author":"Penack","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2018-000348_bb0300","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"key":"10.1136\/esmoopen-2018-000348_bb0305","first-page":"CD003039","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia","volume":"10","author":"Mhaskar","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/esmoopen-2018-000348_bb0310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bmt.1705722","article-title":"Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project","volume":"40","author":"Tigue","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1136\/esmoopen-2018-000348_bb0315","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.CCM.0000048629.32625.5D","article-title":"Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis","volume":"31","author":"Root","year":"2003","journal-title":"Crit Care Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920323279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920323279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2018-000348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:38Z","timestamp":1761855758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920323279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"alternative-id":["S2059702920323279"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000348","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empirical antimicrobial treatment in haemato-\/oncological patients with neutropenic sepsis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2018-000348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000348"}}